Expert Video Report on Targeted Treatments for Advanced NSCLC

ESMO 2018 Congress

Speaker: Fabrice Barlesi

Commenting on the findings from AURA3, FLAURA and GEOMETRY studies presented at ESMO 2018 Congress, Dr. Fabrice Barlesi says that many results have been presented about genotyping and targeted treatments, but these study results bring important information on resistance mechanisms to osimertinib which will be useful for the practice. He details the mechanisms of progression and explains the importance of detecting EGFR and MET mutations in this population of patients.
Dr. Barlesi concludes that genotyping lung cancer patients is essential, it gives key information to understand why patients may progress and provide clinicians with new targeted solutions in some cases at least.

ESMO 2018 Congress abstracts: